

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Oral nirmatrelvir, Comirnaty (Pfizer) effectiveness after COVID-19 recovery, childhood obesity and the risk of SARS-CoV-2 infection

Peer reviewed journals featured:

- A randomised controlled trial of oral nirmatrelvir for high-risk, non-hospitalised COVID-19 adults [here](#)
- Observational studies on:
 - Effectiveness of Comirnaty (Pfizer) vaccine after recovery from COVID-19 [here](#)
 - Protection against SARS-CoV-2 after COVID-19 vaccination and previous infection [here](#)
 - Childhood obesity and the risk of SARS-CoV-2 infection [here](#)
 - SARS-CoV-2 seropositivity during the first 2 waves among Canadian adults [here](#)
 - mRNA vaccine-induced antibodies compared with natural immunity in neutralising SARS-CoV-2 [here](#)
 - The effect of social deprivation on the dynamics of SARS-CoV-2 infection in France [here](#) and associated commentary [here](#)
- A modelling study on associations between deprivation, ethnicity, and SARS-CoV-2 infections in England [here](#)

Letters and correspondence discussed:

- Omicron variant neutralisation in serum from vaccinated and convalescent persons [here](#)
- Pre-existing hypertension associated with long-term post-COVID symptoms and poor sleep quality [here](#)

Pre-peer review articles featured:

- Virological characteristics of Omicron BA.2 lineage [here](#)
- Fourth dose mRNA vaccine immunogenicity & efficacy against Omicron [here](#)
- Low vs standard Vaxzevria (AstraZeneca) booster dose after CoronaVac vaccination in adults [here](#)
- Omicron-specific mRNA vaccine induces potent and broad antibody responses in vivo [here](#)

News and blogs

- Vaccine will be offered to children aged 5–11 years in England, Wales, and Scotland [here](#)
- Vaccinated people are less likely to get long COVID (post-acute COVID-19 syndrome) [here](#)
- COVID-19 reinfections surge during Omicron onslaught [here](#)
- Recruiting innate immunity against SARS-CoV-2 [here](#)
- NEJM audio interviews on nirmatrelvir antiviral for COVID-19 [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).